鼻腔NK/T细胞淋巴瘤的CT及MRI表现

CT and MRI findings of the primary NK/T cell lymphoma in nasal cavity

目的:探讨鼻腔NK/T细胞淋巴瘤的CT及MRI表现特征,旨在提高其诊断准确性。方法:回顾性分析16例经病理证实的鼻腔NK/T细胞淋巴瘤患者的CT和MRI影像学资料。16例均行CT平扫,其中2例行CT增强扫描;16例中8例行MRI检查,其中1例行增强扫描。结果:单侧6例,双侧10例;肿瘤局限于鼻腔内4例,延伸至鼻腔外12例;肿瘤侵犯邻近结构13例,浸润鼻旁或面部皮下组织8例,伴骨质破坏9例。CT显示肿瘤呈软组织密度充填鼻腔并沿鼻黏膜蔓延,增强后轻到中度不均匀强化。MRI T1WI肿瘤呈等信号,信号强度类似或稍低于肌肉;T2WI呈不均匀稍高信号,信号强度高于肌肉但低于鼻黏膜,增强后轻到中度不均匀强化。结论:鼻腔NK/T细胞淋巴瘤影像学表现有一定特征,可提示诊断、显示病变范围和程度,有助于临床准确分期。

Objective： To study the CT and MRI features of primary NK/T cell non-Hodgkin＇s lymphoma in nasal cavity so as to promote the diagnostic accuracy. Materials and Methods： CT and/or MRI findings of 16 cases with nasal cavity NK/T cell lymphoma verified by pathology were analyzed retrospectively. Sixteen cases were examined with CT plain scans and 2 of them were done with CT contrast scans. Eight of the 16 cases were examined with MRI plain scans and 1 of them were examined together with MRI contrast scans. Results： Of all the 16 cases, the tumors involving unilateral nasal cavity in 6, bilateral in 10. The tumor was confined in the nasal cavity in 4, and with extranasal extension in 12. The tumor involvement of adjacent structures in 13 and into subcutaneous soft tissue of the nasal labial fold or face in 8, with the bony destruction in 9. CT showed the nasal cavity was filled with soft tissues and spread along the nasal mucosa, there were mild- to-moderate heterogeneous enhancement on post contrast CT. On T1WI showed the tumors were homogeneous and isointense, the signal intensity was similar to or slightly lower than muscle. On T2WI the tumors showed slightly heterogeneous and hyperintense, the signal intensity was higher than muscle but lower than sinonasal mucosa, there were mild-to-moderate heterogeneous enhancement after gadolinium injection. Conclusion： Primary NK/T cell lymphoma of nasal cavity has certain characteristics in its imaging appearances, the imaging findings can suggest the diagnosis and show ranges and degrees of the lesions and provide more accurate informations for clinical staging.